“Preemptive” Live Donor Liver Transplantation for Fibrolamellar Hepatocellular Carcinoma: A Case Report
✍ Scribed by I. Fouzas; G.C. Sotiropoulos; E.P. Molmenti; S. Beckebaum; K.J. Schmitz; C.E. Broelsch; H. Lang; M. Malagó
- Book ID
- 116934837
- Publisher
- Elsevier Science
- Year
- 2008
- Tongue
- English
- Weight
- 504 KB
- Volume
- 40
- Category
- Article
- ISSN
- 0041-1345
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Liver transplantation is now an acceptable treatment for small hepatocellular carcinomas in the setting of cirrhosis. Larger tumors in cirrhotic livers and unresectable tumors in noncirrhotic livers (including fibrolamellar hepatocellular carcinomas) may also be indications for transplantation. With
Liver transplantation (LT) is the treatment of choice for early hepatocellular carcinoma (HCC) in patients with end-stage liver disease but is limited by the availability of donor organs. Living donor liver transplantation (LDLT) represents an alternative therapeutic option for patients with disease